Strategic Partnerships Rare Genomics Institute has a history of collaborations with diagnostic labs and sequencing providers (DanteLabs, PacBio/HiFi via iHope network) which indicates openness to partner-driven growth. Sales opportunities exist in offering integrated sequencing services, data analysis pipelines, and joint grant-based programs that expand diagnostic capabilities for undiagnosed rare diseases.

Funding and Scale With reported revenue in the mid seven figures and a nonprofit structure, RG operates at a scalable but mission-driven level. This suggests opportunities for grant-aligned sponsorships, philanthropy-led campaigns, and service tier offerings for funded patients or affiliated advocacy groups.

Tech Stack Synergy RG already leverages cloud platforms, AI/ML tooling (PyTorch), and sequencing workflows, presenting a strong base for offering cloud-based data analysis, secure data sharing, and compliant genomic interpretation solutions tailored to rare disease research.

Global Network References to international expansion through iHope and collaborations indicate an appetite for cross-border diagnostics programs. Sales pitches can emphasize multinational service delivery, remote sequencing coordination, and support for clinics or advocacy groups across regions.

Advocacy and Reach Active patient advocacy community and annual grant competitions highlight RG’s access to patient cohorts and researchers. This creates opportunities to offer study recruitment services, patient deduplication and consent management tools, and co-branded education resources to accelerate rare disease research.